SLF2

Across TCGA pan-cancer cohorts, SLF2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLF2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLF2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, KIRC, and STAD are the cancer types where SLF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.239	0.610	.005	30	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
STAD	OS	Median	All	0.199	0.730	.002	12	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
PRAD	DFS	Median	All	0.176	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.682	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLF2–HNSC (OS)

Open the HNSC breakdown →